Abstract 3224: Cilostazol Attenuates Angiographic Restenosis in Patients with Femoro-popliteal Lesions
Background: We have previously demonstrated in a prospective study that orally administered cilostazol reduces the frequency of target lesion revascularization (TLR) after successful percutaneous peripheral intervention (PPI) for de novo femoro-popliteal (FP) lesions. However, whether cilostazol has mere antiplatelet/vasodilation effects or reduces angiographic restenosis remains unclear. We sought to investigate whether cilostazol reduces the binary restenosis after successful PPI for de novo FP lesions by angiographic follow-up.
Method: From March 2004 to June 2005, 127 patients were randomized to receive either cilostazol (CIL) or ticlopidine (TIC) in combination with aspirin (the basic drug) after successful PPI for FP lesions. Of these, 22 patients dropped out due to adverse drug effects, amputation, or death. Follow-up angiography was performed 7.5±2.8 months after PPI. except for 17 patients, yielding 88 patients enrolled (CIL: n=39; TIC: n=49). Binary restenosis as well as the rate of TLR was compared between CIL and TIC.
Results: Patient, lesion and procedural characteristics of patients were not significantly different between the groups. No thrombotic occlusion occurred during the follow-up. TLR was significantly less in CIL than in TIC (10% versus 41%, p<0.005). By follow-up angiography, the patients with CIL had smaller % diameter stenosis than TIC (42% versus 56%, p<0.05). Late loss tended to be lower in CIL than TIC (2.2 mm versus 2.8 mm, p=0.076).
Conclusion: Cilostazol not only reduces TLR, but attenuates angiographic restenosis after PPI in. the FP lesions.